$2.30
0[0.00%]
Last update: 9:32AM Get Real Time Here
Taysha Gene Therapies
(NASDAQ:TSHA)Taysha Gene Therapies Stock (NASDAQ:TSHA), Analyst Ratings, Price Targets, Predictions
Taysha Gene Therapies Inc has a consensus price target of $8.56, established from looking at the 72 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald, Cantor Fitzgerald, and Needham on April 19, 2024, April 18, 2024, and April 11, 2024. With an average price target of $7 between Cantor Fitzgerald, Cantor Fitzgerald, and Needham, there's an implied 204.35% upside for Taysha Gene Therapies Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Needham
Piper Sandler
Canaccord Genuity
Chardan Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Taysha Gene Therapies
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/19/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 04/18/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 04/11/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Needham | Gil Blum | → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 291.3% | Piper Sandler | Christopher Raymond | → $9 | Initiates | → Overweight | Get Alert |
| 03/21/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Canaccord Genuity | Whitney Ijem | → $7 | Reiterates | Buy → Buy | Get Alert |
| 03/21/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Chardan Capital | Geulah Livshits | $5 → $7 | Maintains | Buy | Get Alert |
| 03/20/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 117.39% | JMP Securities | Silvan Tuerkcan | → $5 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/20/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Needham | Gil Blum | $5 → $7 | Maintains | Buy | Get Alert |
| 02/29/2024 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 117.39% | Needham | Gil Blum | → $5 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Cantor Fitzgerald | Kristen Kluska | → $7 | Reiterates | Overweight → Overweight | Get Alert |
| 11/15/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Cantor Fitzgerald | Kristen Kluska | $6 → $7 | Maintains | Overweight | Get Alert |
| 09/20/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 117.39% | Needham | Gil Blum | → $5 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 117.39% | Truist Securities | Joon Lee | $6 → $5 | Maintains | Buy | Get Alert |
| 09/20/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 160.87% | Canaccord Genuity | Whitney Ijem | $7 → $6 | Maintains | Buy | Get Alert |
| 08/16/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 204.35% | Canaccord Genuity | Whitney Ijem | $13 → $7 | Maintains | Buy | Get Alert |
| 08/15/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 160.87% | Truist Securities | Joon Lee | $2 → $6 | Maintains | Buy | Get Alert |
| 08/15/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 73.91% | JMP Securities | Silvan Tuerkcan | → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/15/2023 | TSHA | Buy Now | Taysha Gene Therapies | $2.30 | 247.83% | Baird | Jack Allen | $6 → $8 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Taysha Gene Therapies (TSHA)?
The latest price target for Taysha Gene Therapies (NASDAQ: TSHA) was reported by Cantor Fitzgerald on April 19, 2024. The analyst firm set a price target for $7.00 expecting TSHA to rise to within 12 months (a possible 204.35% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Taysha Gene Therapies (TSHA)?
The latest analyst rating for Taysha Gene Therapies (NASDAQ: TSHA) was provided by Cantor Fitzgerald, and Taysha Gene Therapies reiterated their overweight rating.
When was the last upgrade for Taysha Gene Therapies (TSHA)?
There is no last upgrade for Taysha Gene Therapies.
When was the last downgrade for Taysha Gene Therapies (TSHA)?
The last downgrade for Taysha Gene Therapies Inc happened on February 2, 2023 when BTIG changed their price target from N/A to N/A for Taysha Gene Therapies Inc.
When is the next analyst rating going to be posted or updated for Taysha Gene Therapies (TSHA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Taysha Gene Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Taysha Gene Therapies was filed on April 19, 2024 so you should expect the next rating to be made available sometime around April 19, 2025.
Is the Analyst Rating Taysha Gene Therapies (TSHA) correct?
While ratings are subjective and will change, the latest Taysha Gene Therapies (TSHA) rating was a reiterated with a price target of $0.00 to $7.00. The current price Taysha Gene Therapies (TSHA) is trading at is $2.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.